Royalty Pharma to Present at Upcoming Investor Conferences

Rhea-AI Summary

Royalty Pharma plc (Nasdaq: RPRX) is set to participate in several investor conferences this September. Key dates include Citi’s 17th Annual BioPharma Conference on September 8 at 11:20 a.m. ET, Morgan Stanley’s Global Healthcare Conference on September 12 at 10:30 a.m. ET, and Bank of America’s Healthcare Conference on September 15 at 10:55 a.m. ET. Webcasts will be available on Royalty Pharma’s Events page and archived for thirty days. The company, established in 1996, is the leading buyer of biopharmaceutical royalties, focusing on funding innovation across the industry.

NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of September:

• Citi’s 17th Annual BioPharma Conference on Thursday, September 8 at 11:20 a.m. ET
• Morgan Stanley’s 20th Annual Global Healthcare Conference on Monday, September 12 at 10:30 a.m. ET
• Bank of America’s Global Healthcare Conference 2022 on Thursday, September 15 at 10:55 a.m. ET / 3:55 p.m. BST
  

The webcasts will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/news-and-events/events. Webcasts will also be archived for a minimum of thirty days.

About Royalty Pharma plc

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, Kalydeco, Orkambi and Symdeko, Biogen’s Tysabri, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, GSK’s Trelegy, Novartis’ Promacta, Biohaven and Pfizer’s Nurtec ODT, Johnson & Johnson’s Tremfya, Roche’s Evrysdi, Gilead’s Trodelvy, and 11 development-stage product candidates.

Royalty Pharma Investor Relations and Communications

+1 (212) 883-6772
ir@royaltypharma.com

FAQ

What conferences will Royalty Pharma (RPRX) attend in September 2022?

Royalty Pharma will attend Citi’s BioPharma Conference on September 8, Morgan Stanley’s Global Healthcare Conference on September 12, and Bank of America’s Healthcare Conference on September 15, 2022.

When is Royalty Pharma's presentation at Citi's BioPharma Conference?

Royalty Pharma's presentation at Citi's 17th Annual BioPharma Conference is scheduled for September 8, 2022, at 11:20 a.m. ET.

Where can I find the webcasts of Royalty Pharma's investor presentations?

The webcasts of Royalty Pharma's investor presentations will be accessible on their Events page and archived for a minimum of thirty days.

What is the significance of Royalty Pharma's participation in investor conferences?

Royalty Pharma's participation in investor conferences highlights its commitment to engaging with investors and showcases its innovations in the biopharmaceutical industry.